ClinicalTrials.gov registry snapshot / 2026-07-24

Peptide trials,
without the maze.

Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.

268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program

Study status is not drug rank.

Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.

Official registry finder

Filter the exact records.

Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.

Reset
9matching registry records
Matching recruiting site observations8
Program and recordStatusPhase and enrollmentLocationsPrimary completionRegistry updateSource
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444 / Boehringer IngelheimRecruitingVerified 2026-07Phase 31,800 estimated5 matching recruitingAmsterdam, 1081HV, Netherlands / Dordrecht, 3318 AT, Netherlands / Nijmegen, 6525 GA, Netherlands / 2 more areasDec 27, 2031estimatedJul 9, 2026ClinicalTrials.govOpen NCT06632444
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisNCT06632457 / Boehringer IngelheimRecruitingVerified 2026-07Phase 31,590 estimated3 matching recruitingDordrecht, 3318 AT, Netherlands / Rotterdam, 3015 GD, Netherlands / Schiedam, 3118 JH, NetherlandsJun 5, 2029estimatedJul 9, 2026ClinicalTrials.govOpen NCT06632457
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverNCT05202353 / Boehringer IngelheimActive, not recruitingVerified 2026-07Phase 129 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Dec 2, 2026estimatedJul 22, 2026ClinicalTrials.govOpen NCT05202353
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightNCT04667377 / Boehringer IngelheimCompletedVerified 2023-10Registry results postedPhase 2387 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Sep 15, 2022actualNov 2, 2023ClinicalTrials.govOpen NCT04667377
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)NCT04771273 / Boehringer IngelheimCompletedVerified 2024-11Registry results postedPhase 2295 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Nov 9, 2023actualDec 3, 2024ClinicalTrials.govOpen NCT04771273
A Study in Healthy Men to Test How BI 456906 is Processed in the BodyNCT05421338 / Boehringer IngelheimCompletedVerified 2022-12Phase 16 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Nov 17, 2022actualDec 14, 2022ClinicalTrials.govOpen NCT05421338
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT06066515 / SYNCHRONIZE™-1 / Boehringer IngelheimCompletedVerified 2026-03Phase 3726 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Dec 2, 2025actualMar 12, 2026ClinicalTrials.govOpen NCT06066515
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightNCT06066528 / SYNCHRONIZE™-2 / Boehringer IngelheimCompletedVerified 2026-06Phase 3755 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Dec 12, 2025actualJun 24, 2026ClinicalTrials.govOpen NCT06066528
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 / Boehringer IngelheimCompletedVerified 2026-07Phase 35,531 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Jun 1, 2026actualJul 23, 2026ClinicalTrials.govOpen NCT06077864
Clinical trial finder FAQ

Status, location, and enrollment are different fields.

These answers prevent the most common registry-search errors before a reader follows an official source.

01

Are any Retatrutide clinical trials recruiting?

Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.

02

How do I find a peptide clinical trial near me?

Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.

03

Does Recruiting mean I can join the trial?

No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.

04

Are the drugs in this clinical trial finder FDA approved?

A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.

05

Why do only some registry records show posted results?

11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.

06

How current is the peptide clinical trial data?

The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.

Evidence boundary

A registry finder, not an enrollment service.

A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.

Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.

Read the official API documentation ↗Understand evidence categories →